Pacritinib

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 221 publications

Managing myelofibrosis in the frailty era: the expanding role of JAK inhibitors.

Managing myelofibrosis in the frailty era: the expanding role of JAK inhibitors.

Journal: Leukemia & lymphoma

Published: April 15, 2026

A pharmacological profile of pacritinib for the treatment of myelofibrosis.

A pharmacological profile of pacritinib for the treatment of myelofibrosis.

Journal: Expert review of clinical pharmacology

Published: April 08, 2026

Experimental JAK inhibitors: the current, present, and future in graft-versus-host disease management?

Experimental JAK inhibitors: the current, present, and future in graft-versus-host disease management?

Journal: Expert opinion on investigational drugs

Published: March 11, 2026

JAK Inhibitors in the Treatment of T-Cell Lymphomas: Current Evidence and Future Directions.

JAK Inhibitors in the Treatment of T-Cell Lymphomas: Current Evidence and Future Directions.

Journal: Cancers

Published: January 08, 2026

Current treatments, practical management, and emerging investigational therapies for myelofibrosis.

Current treatments, practical management, and emerging investigational therapies for myelofibrosis.

Journal: Expert review of hematology

Published: December 14, 2025

Pacritinib in patients with myelodysplastic/myeloproliferative neoplasms.

Pacritinib in patients with myelodysplastic/myeloproliferative neoplasms.

Journal: Leukemia & lymphoma

Published: November 26, 2025

PAXIS: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Phase 2 Study (Part 1) Followed by an Open-Label Period (Part 2) to Assess the Efficacy and Safety of Pacritinib in Patients with VEXAS Syndrome.

PAXIS: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Phase 2 Study (Part 1) Followed by an Open-Label Period (Part 2) to Assess the Efficacy and Safety of Pacritinib in Patients with VEXAS Syndrome.

Journal: Journal of clinical medicine

Published: November 16, 2025

Is there a best JAK inhibitor in myelofibrosis when it comes to safety and anemia outcomes?

Is there a best JAK inhibitor in myelofibrosis when it comes to safety and anemia outcomes?

Journal: Future oncology (London, England)

Published: November 04, 2025

Modulation of IRF7-driven transcription as a strategy to control HIV-1 latency.

Modulation of IRF7-driven transcription as a strategy to control HIV-1 latency.

Journal: Frontiers in immunology

Published: October 29, 2025

Post-FDA Approval Experience With Momelotinib in JAK Inhibitor-Naïve Myelofibrosis: Focus on Anemia Response and Treatment-Emergent Nephropathy and Peripheral Neuropathy.

Post-FDA Approval Experience With Momelotinib in JAK Inhibitor-Naïve Myelofibrosis: Focus on Anemia Response and Treatment-Emergent Nephropathy and Peripheral Neuropathy.

Journal: American journal of hematology

Published: October 23, 2025

Pacritinib in transplant-eligible myelofibrosis: final analysis of the phase II HOVON-134 trial.

Pacritinib in transplant-eligible myelofibrosis: final analysis of the phase II HOVON-134 trial.

Journal: Bone marrow transplantation

Published: October 20, 2025

Real-world experience with pacritinib for patients with myelofibrosis refractory to ruxolitinib: a report of three cases.

Real-world experience with pacritinib for patients with myelofibrosis refractory to ruxolitinib: a report of three cases.

Journal: Hospital practice (1995)

Published: October 17, 2025

Showing 1-12 of 221

Last Updated: 04/28/2026